Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 18;66(10):e0075122.
doi: 10.1128/aac.00751-22. Epub 2022 Sep 14.

Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria

Abiu Sempere  1   2 , Belén Viñado  3   4 , Ibai Los-Arcos  1   2   4 , David Campany  5 , Nieves Larrosa  2   3   4   6 , Nuria Fernández-Hidalgo  1   2   4   6 , Dolors Rodríguez-Pardo  1   2   4   6 , Juan José González-López  2   3   4   6 , Xavier Nuvials  2   7   8 , Benito Almirante  1   2   4   6 , Laura Escolà-Vergé  1   2   4   6
Affiliations

Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria

Abiu Sempere et al. Antimicrob Agents Chemother. .

Abstract

This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were Enterobacterales in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.

Keywords: MBL; VIM; aztreonam; ceftazidime-avibactam; metallo-β-lactamase.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. I. Los-Arcos has received honoraria for speaking at educational events from MSD and Pfizer and has received travel support from Gilead, Merck and Novartis for scientific purposes. D. Rodriguez-Pardo declares no conflicts of interest in relation to this work. Regarding other activities outside this study, D. Rodriguez-Pardo declares having received honoraria from Pfizer, Angellini, MSD and Astellas as payment for lectures, consultancy tasks and travel/accommodation for scientific purposes. X. Nuvials has received honoraria from MSD, Pfizer, Gilead and Shionogi as payment for speaking at educational events and consultancy tasks. B. Almirante has received honoraria for speaking at educational events from MSD, Pfizer, Gilead Sciences, Shionogi and Angellini and has received research funding from Gilead Sciences, MSD and Pfizer. L. Escolà-Vergé declares no conflicts of interest in relation to this work. Regarding other activities, L. Escolà-Vergé has received travel/accommodation support from Pfizer and MSD for scientific purposes.

The authors declare a conflict of interest. I. Los-Arcos has received honoraria for speaking at educational events from MSD and Pfizer and has received travel support from Gilead, Merck and Novartis for scientific purposes. D. Rodriguez-Pardo declares no conflicts of interest in relation to this work. Regarding other activities outside this study, D. Rodriguez-Pardo declares having received honoraria from Pfizer, Angellini, MSD and Astellas as payment for lectures, consultancy tasks and travel/accommodation for scientific purposes. X.Nuvials has received honoraria from MSD, Pfizer, Gilead and Shionogi as payment for speaking at educational events and consultancy tasks. B. Almirante has received honoraria for speaking at educational events from MSD, Pfizer, Gilead Sciences, Shionogi and Angellini and has received research funding from Gilead Sciences, MSD and Pfizer. L. Escolà-Vergé declares no conflicts of interest in relation to this work. Regarding other activities, L. Escolà-Vergé has received travel/accommodation support from Pfizer and MSD for scientific purposes.

References

    1. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. 2018. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31:e00079-17. doi:10.1128/CMR.00079-17. - DOI - PMC - PubMed
    1. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. 2021. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P aeruginosa). Clin Infect Dis 72:e169–e183. doi:10.1093/cid/ciaa1478. - DOI - PubMed
    1. Shields RK, Doi Y. 2020. Aztreonam combination therapy: an answer to metallo-β-lactamase-producing Gram-negative bacteria? Clin Infect Dis 71:1099–1101. doi:10.1093/cid/ciz1159. - DOI - PMC - PubMed
    1. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61:e02243-16. doi:10.1128/AAC.02243-16. - DOI - PMC - PubMed
    1. Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. 2019. The “old” and the “new” antibiotics for MDR Gram-negative pathogens: for whom, when, and how. Front Public Health 7:151. doi:10.3389/fpubh.2019.00151. - DOI - PMC - PubMed

Publication types